<DOC>
	<DOCNO>NCT01380938</DOCNO>
	<brief_summary>WRITE study aim identify effectiveness innovative individualize schedule treatment compare standard regimen patient chronic HCV genotype 2 3 .</brief_summary>
	<brief_title>Different Ribavirin Dosages Different Duration Treatment Combination With PegInterferon Patients With Genotype 2 3 ( WRITE )</brief_title>
	<detailed_description>The investigator go compare weight-based dosage ribavirin , combination Peginterferon alpha-2a , standard fix dosage 800 mg . Patients evaluate week 4 assay sensitivity 15 IU/ml . Patients week 4 response discontinue treatment week 12 arm . Patients HCV RNA still detectable week 4 receive 1000-1200 mg ribavirin arm A discontinue treatment week 24 , whereas patient HCV RNA still detectable week 4 receive 800 mg ribavirin arm B treat till week 48 . A standard treatment arm ( C ) include patient treat 24 week Peginterferon alpha-2a fix 800 mg ribavirin dosage use control arm .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronic hepatitis C virus ( HCV ) infection ( HCVAb HCV RNA positive ) Patients HCV genotype 2 3 Age 1870 year Na√Øve patient previously treat standard interferon monotherapy Female patient childbearing age agree avoid pregnancy period treatment 24 week end treatment Previous treatment ribavirin Cirrhosis ( CHILD PUGH B C ) Evidence Hepatocellular carcinoma Pregnancy Retinopathy class I II Alcohol consumption &gt; 40 gr/day Chronic cardiac respiratory disease HIV HBsAg HDV positivity Hemoglobin &lt; 8.5 gr/dL WBC &lt; 3.500/mm3 PLT &lt; 80.000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>genotype 2 3</keyword>
	<keyword>combination treatment</keyword>
	<keyword>individualize treatment</keyword>
</DOC>